Management of follow-up of neuroendocrine neoplasias

Publication date: Available online 23 February 2016 Source:Best Practice & Research Clinical Endocrinology & Metabolism Author(s): Ulrich-Frank Pape, Sebastian Maasberg, Henning Jann, René Pschowski, Sandrine Krüger, Vikas Prasad, Timm Denecke, Bertram Wiedenmann, Andreas Pascher Neuroendocrine neoplasias (NEN) comprise heterogeneous epithelial neoplasms with a large variety of clinical presentations, treatment options and outcomes. Since potentially all NEN bear malignant potential it is important for long-term clinical management and improvement of outcome to decide on successful and oncologically and economically meaningful follow-up strategies. Evidence-based outcome data validating specific follow-up strategies are, however, not available to date and thus outcome data, known prognostic factors and clinical experience guide the decisions on follow-up regimens. The review summarizes general recommendations as well as specific considerations based on tumor entities, clinicopathological tumor characteristics and clinical experience. Follow-up shall serve the patient to improve outcome, benefit from more effective therapies and suffer less from unnecessary and/or toxic therapeutic interventions and finally preserve or gain a good quality of life.

Source: Best Practice and Research Clinical Endocrinology and Metabolism - February 23, 2016 Category: Endocrinology Source Type: research